Barclays’s Cartesian Therapeutics RNAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $20.3K | Sell |
3,307
-14,344
| -81% | -$102K | ﹤0.01% | 4574 |
|
|
2025
Q4 | $127K | Sell |
17,651
-191
| -1% | -$1.54K | ﹤0.01% | 4506 |
|
|
2025
Q3 | $182K | Sell |
17,842
-12,833
| -42% | -$144K | ﹤0.01% | 4370 |
|
|
2025
Q2 | $319K | Buy |
30,675
+16,306
| +113% | +$174K | ﹤0.01% | 4018 |
|
|
2025
Q1 | $189K | Sell |
14,369
-4,730
| -25% | -$84.5K | ﹤0.01% | 4072 |
|
|
2024
Q4 | $342K | Buy |
19,099
+7,488
| +64% | +$152K | ﹤0.01% | 4050 |
|
|
2024
Q3 | $187K | Buy |
11,611
+7,849
| +209% | +$123K | ﹤0.01% | 4337 |
|
|
2024
Q2 | $102K | Sell |
3,762
-203
| -5% | -$4.84K | ﹤0.01% | 3894 |
|
|
2024
Q1 | $77.3K | Sell |
3,965
-2,707
| -41% | -$57.4K | ﹤0.01% | 4519 |
|
|
2023
Q4 | $138K | Buy |
6,672
+4,683
| +235% | +$140K | ﹤0.01% | 4549 |
|
|
2023
Q3 | $63.2K | Sell |
1,989
-52
| -3% | -$1.74K | ﹤0.01% | 3764 |
|
|
2023
Q2 | $68.6K | Buy |
2,041
+774
| +61% | +$27.7K | ﹤0.01% | 3713 |
|
|
2023
Q1 | $52.8K | Hold |
1,267
| – | – | ﹤0.01% | 4430 |
|
|
2022
Q4 | $42.9K | Sell |
1,267
-38
| -3% | -$1.62K | ﹤0.01% | 4601 |
|
|
2022
Q3 | $64K | Sell |
1,305
-79
| -6% | -$4.34K | ﹤0.01% | 3702 |
|
|
2022
Q2 | $54K | Sell |
1,384
-513
| -27% | -$15.2K | ﹤0.01% | 4012 |
|
|
2022
Q1 | $70K | Sell |
1,897
-1,827
| -49% | -$114K | ﹤0.01% | 3954 |
|
|
2021
Q4 | $365K | Buy |
3,724
+2,487
| +201% | +$268K | ﹤0.01% | 3333 |
|
|
2021
Q3 | $155K | Buy |
1,237
+268
| +28% | +$32.4K | ﹤0.01% | 3739 |
|
|
2021
Q2 | $121K | Sell |
969
-1,305
| -57% | -$155K | ﹤0.01% | 3771 |
|
|
2021
Q1 | $309K | Buy |
2,274
+307
| +16% | +$38.1K | ﹤0.01% | 3487 |
|
|
2020
Q4 | $178K | Sell |
1,967
-581
| -23% | -$50.4K | ﹤0.01% | 3828 |
|
|
2020
Q3 | $190K | Buy |
2,548
+70
| +3% | +$5.36K | ﹤0.01% | 3888 |
|
|
2020
Q2 | $210K | Buy |
2,478
+1,241
| +100% | +$112K | ﹤0.01% | 4037 |
|
|
2020
Q1 | $89K | Buy |
+1,237
| New | +$119K | ﹤0.01% | 4881 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 6739 |
|
|
2019
Q3 | – | Sell |
-87
| Closed | -$4K | – | 7057 |
|
|
2019
Q2 | $4K | Sell |
87
-235
| -73% | -$16K | ﹤0.01% | 6732 |
|
|
2019
Q1 | $23K | Sell |
322
-100
| -24% | -$6.34K | ﹤0.01% | 6301 |
|
|
2018
Q4 | $34K | Buy |
422
+197
| +88% | +$45K | ﹤0.01% | 5676 |
|
|
2018
Q3 | $105K | Buy |
225
+181
| +411% | +$72.7K | ﹤0.01% | 5499 |
|
|
2018
Q2 | $17K | Sell |
44
-53
| -55% | -$18.8K | ﹤0.01% | 6278 |
|
|
2018
Q1 | $30K | Sell |
97
-4
| -4% | -$1.14K | ﹤0.01% | 6246 |
|
|
2017
Q4 | $30K | Buy |
101
+45
| +80% | +$19.7K | ﹤0.01% | 6074 |
|
|
2017
Q3 | $31K | Buy |
56
+4
| +8% | +$2.13K | ﹤0.01% | 5595 |
|
|
2017
Q2 | $31K | Buy |
52
+51
| +5,100% | +$22.5K | ﹤0.01% | 5595 |
|
|
2017
Q1 | $0 | Buy |
+1
| New | +$421 | ﹤0.01% | 6941 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 6796 |
|
Other funds holding RNAC
VCM
6CM
EAM
Barclays's RNAC Position: Q1 2026 in Review
Barclays reduced its Cartesian Therapeutics (RNAC) stake by 81% in Q1 2026, selling an estimated $102K and leaving 3,307 shares worth $20.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4574.
Barclays first reported a position in RNAC in Q1 2017 and has held it in 35 quarters since. The position peaked at $365K in Q4 2021. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.
- Barclays held 3,307 shares of Cartesian Therapeutics worth $20.3K as of Q1 2026.
- Barclays sold 14,344 Cartesian Therapeutics shares in Q1 2026, an estimated $102K.
- Cartesian Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4574 holding.
- Barclays first reported a position in Cartesian Therapeutics in Q1 2017 and has held it in 35 quarters since.
- Barclays's Cartesian Therapeutics position peaked at $365K in Q4 2021.
- 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.